Switching back from infliximab biosimilar SB2 to reference infliximab (Remicade) did not affect clinical disease activity or ...
Switching from IV to subcutaneous infliximab maintenance therapy is associated with high treatment persistence and a stable ...
Switching back from infliximab biosimilar SB2 to reference infliximab (Remicade) did not affect clinical disease activity or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback